FULC
MaterialsFulcrum Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving FULC Today?
No stock-specific AI insight has been generated for FULC yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
FULC News
20 articles- Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·Apr 28, 2026
- Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·Apr 27, 2026
- Fulcrum Therapeutics Q1 Earnings Call HighlightsMarketbeat·Apr 27, 2026
- Fulcrum (FULC) Q1 2026 Earnings TranscriptMotley Fool·Apr 27, 2026
- Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform ExpectationsAdvfn·Apr 27, 2026
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026Yahoo Finance·Apr 27, 2026
- Fulcrum Therapeutics Appoints Josh Lehrer to its Board of DirectorsYahoo Finance·Apr 27, 2026
- Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ETYahoo Finance·Apr 20, 2026
- Agios Rallies On A Surprise FDA Move In Sickle Cell, Pulling Rival Fulcrum HigherYahoo Finance·Mar 31, 2026
- MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell DiseaseYahoo Finance·Mar 19, 2026
- Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval TalkMarketbeat·Mar 17, 2026
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 6, 2026
- Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceYahoo Finance·Mar 3, 2026
- Fulcrum Therapeutics move lower ‘overdone,’ says StifelYahoo Finance·Feb 25, 2026
- Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Feb 25, 2026
- Fulcrum Therapeutics Q4 Earnings Call HighlightsMarketbeat·Feb 24, 2026
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025Yahoo Finance·Feb 24, 2026
- Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseYahoo Finance·Feb 24, 2026
- Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseYahoo Finance·Feb 17, 2026
- Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?Yahoo Finance·Feb 12, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.